Yes there is a 13% discount to NAV floor here but in the last few days the price action has made the offer more enticing for existing share holders. Not to mention the falling NAV. ooof
"The subscription price per share of Common Stock (the "Subscription Price") will be determined by the Fund on the expiration date of the Offer, which is currently expected to be May 17, 2022, unless extended by the Fund (the "Expiration Date"). The Subscription Price will be equal to 92.5% of the average of the last reported sales price of a share of Common Stock of the Fund on the NYSE American on the Expiration Date and each of the four (4) immediately preceding trading days (the "Formula Price"). If, however, the Formula Price is less than 87% of the Fund's net asset value ("NAV") per share of Common Stock at the close of trading on the NYSE American on the Expiration Date, the Subscription Price will be 87% of the Fund's NAV per share of Common Stock at the close of trading on the NYSE American on that day."
N
Long 2,500 shares, DRIP shares each month, will start taking income in a few years. Income for as long as I"m around to collect.
Y
Neuberger Berman High Yield Strategies Fund reached a 52 Week low at 9.15
Y
Neuberger Berman High Yield Strategies Fund reached a 52 Week low at 9.40
Y
Neuberger Berman High Yield Strategies Fund reached a 52 Week low at 9.65
Y
Neuberger Berman High Yield Strategies Fund reached a 52 Week low at 9.76
Y
Neuberger Berman High Yield Strategies Fund is down 5.19% to 10.77
Y
Neuberger Berman High Yield Strategies Fund is up 5.31% to 12.09
NOICE!! GenQA - Optical Genome Mapping Webinar - October 14, 2021 - GenQA is operated by Oxford University NHS Foundation Trust... #bionano #genomics #GenQA #oxford #NHS
Genetic testing has developed significantly over the past few years and the International System for Human Cytogenomic Nomenclature (ISCN) is continuously reviewed to reflect these changes.
Our next Focus On session will be a review of the acquired nomenclature in ISCN 2020. The webinar will take place at 11am GMT (12.00 BST) on 14th October 2021.
The webinar will include:
Review of Acquired ISCN: review of acquired nomenclature in ISCN 2020, including:
-Karyotyping -FISH for break apart, dual and triple fusion probes -Region specific assays -Arrays -Optical Genome Mapping (OGM)
Yes there is a 13% discount to NAV floor here but in the last few days the price action has made the offer more enticing for existing share holders. Not to mention the falling NAV. ooof
"The subscription price per share of Common Stock (the "Subscription Price") will be determined by the Fund on the expiration date of the Offer, which is currently expected to be May 17, 2022, unless extended by the Fund (the "Expiration Date"). The Subscription Price will be equal to 92.5% of the average of the last reported sales price of a share of Common Stock of the Fund on the NYSE American on the Expiration Date and each of the four (4) immediately preceding trading days (the "Formula Price"). If, however, the Formula Price is less than 87% of the Fund's net asset value ("NAV") per share of Common Stock at the close of trading on the NYSE American on the Expiration Date, the Subscription Price will be 87% of the Fund's NAV per share of Common Stock at the close of trading on the NYSE American on that day."
Genetic testing has developed significantly over the past few years and the International System for Human Cytogenomic Nomenclature (ISCN) is continuously reviewed to reflect these changes.
Our next Focus On session will be a review of the acquired nomenclature in ISCN 2020. The webinar will take place at 11am GMT (12.00 BST) on 14th October 2021.
The webinar will include:
Review of Acquired ISCN: review of acquired nomenclature in ISCN 2020, including:
-Karyotyping
-FISH for break apart, dual and triple fusion probes
-Region specific assays
-Arrays
-Optical Genome Mapping (OGM)
https://eqa.genqa.org/c/sites/default/files/Acquired%20ISCN%20beginners.pdf
https://genqa.org/events/all